HIND Share Price Performance
US$2.18
-6.55 (-75.03%)
81.0% undervalued intrinsic discount
US$11.50
Fair Value
Price US$2.18
AnalystConsensusTarget US$11.50
Fair ValueUS$11.50
Share Pricen/a
Vyome Holdings, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
HIND Community Narratives
AN
Fair Value
·Fair Value US$11.5 81.0% undervalued intrinsic discount
Rare Disease And Immuno Inflammatory Pipeline Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rare Disease And Immuno Inflammatory Pipeline Will Drive Long Term Upside Potential
Catalysts About Vyome Holdings Vyome Holdings focuses on immuno-inflammatory and rare disease therapeutics with lead asset VT-1953 for malignant fungating wounds. What are the underlying business or industry changes driving this perspective?Read more
AN
US$11.5
81.0% undervalued intrinsic discount
Fair Value
Profit Margin
21.93%
Future PE
43.16x
Price in 2029
US$17.37
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Rare Disease And Immuno Inflammatory Pipeline Will Drive Long Term Upside Potential
Fair Value: US$11.5 81.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vyome Holdings, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -1.61
- 52.74%
- -8,716.70%
- 0%
About HIND
- Founded
- n/a
- Employees
- 14
- CEO
- WebsiteView website
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
